Norgine

Azanta A/S is a biopharmaceutical company based in Copenhagen, Denmark, founded in 1994. The company specializes in developing and marketing treatments for orphan oncology and women's health conditions, along with offering products related to obstetrics and addiction medicine. Azanta's product portfolio includes several pharmaceuticals such as Nimorazole, a hypoxic radiosensitizer for head and neck cancer, and Angusta, used for labor induction. Other notable products include Amnisure, Cicatridina, Repadina Plus, Cystistat, Flexi-T, Methadone, Oxandrin, and Suplasyn. In February 2010, the company changed its name from IPC International A/S and has since operated as a subsidiary of Norgine B.V. Azanta aims to provide effective healthcare solutions in its specialized areas.

The Merus corporate growth strategy is driven by a product acquisition plan which employs an opportunistic approach to source product acquisition candidates. This approach allows Merus to source pharmaceutical products across broad therapeutic classes which provides access to acquisition targets not available to other players and creates a diversified strategy. Although Merus has a broad therapeutic focus, opportunities will be pursued if the application of a dedicated small scale sales force can deliver incremental product sales growth. The geographic focus will be the United States and Canada